Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis treatments may impact bone health, new study finds

NCT ID NCT07140666

Knowledge-focused Sponsor: Chongli Yu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 100 adults with moderate-to-severe psoriasis to see how two common biologic drugs, Secukinumab and Adalimumab, affect bone density. Researchers measured bone mineral density in the spine and hip over time. The goal was to understand if these treatments help or harm bone health, since psoriasis itself may raise the risk of osteoporosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secukinumab and Adalimumab
What this could lead to
If successful, this could help doctors choose psoriasis treatments that also protect bone health, reducing the risk of osteoporosis.
What could go wrong
This is a small, completed observational study, not a treatment trial. Results may not apply to all patients, and it does not test a new drug or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Aug 2022

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a retrospective cohort study conducted at the Department of Dermatology, First Medical Center of Chinese PLA General Hospital. The study population consists of adult patients diagnosed with psoriasis, with or without psoriatic arthritis, who received clinical care at the dermatology department. Patients were managed with conventional systemic therapies, adalimumab, or secukinumab, and clinical records were reviewed to assess bone mineral density, bone metabolism markers, and related outcomes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 18 years or older. * Clinically confirmed diagnosis of psoriasis (with or without psoriatic arthritis). * Currently receiving one of the following treatments: TNF-α inhibitor (adalimumab), or IL-17A inhibitor (secukinumab). * Able and willing to undergo bone mineral density (BMD) assessment using dual-energy X-ray absorptiometry (DXA). * Signed informed consent provided. Exclusion Criteria * History of other systemic diseases affecting bone metabolism (e.g., primary hyperparathyroidism, severe chronic kidney disease, Cushing's syndrome). * Current use of medications known to strongly affect bone metabolism (e.g., long-term corticosteroids, bisphosphonates, denosumab, teriparatide). * Pregnant or breastfeeding women. * History of malignancy or other autoimmune diseases requiring systemic immunosuppressive therapy. * Inability to complete study visits, assessments, or provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Chinese PLA General Hosptial

    Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.